Compare OSW & AVDL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | OSW | AVDL |
|---|---|---|
| Founded | 2017 | 2015 |
| Country | Bahamas | Ireland |
| Employees | N/A | N/A |
| Industry | Hotels/Resorts | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.2B | 2.1B |
| IPO Year | N/A | 1996 |
| Metric | OSW | AVDL |
|---|---|---|
| Price | $21.40 | $21.60 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 3 | 9 |
| Target Price | ★ $24.33 | $18.38 |
| AVG Volume (30 Days) | 538.9K | ★ 1.6M |
| Earning Date | 10-29-2025 | 11-04-2025 |
| Dividend Yield | ★ 0.94% | N/A |
| EPS Growth | ★ 40.79 | N/A |
| EPS | ★ 0.70 | N/A |
| Revenue | ★ $936,080,000.00 | $248,517,000.00 |
| Revenue This Year | $8.68 | $65.47 |
| Revenue Next Year | $8.04 | $30.88 |
| P/E Ratio | $30.54 | ★ N/A |
| Revenue Growth | 7.27 | ★ 79.88 |
| 52 Week Low | $14.21 | $6.38 |
| 52 Week High | $23.49 | $23.57 |
| Indicator | OSW | AVDL |
|---|---|---|
| Relative Strength Index (RSI) | 56.75 | 59.89 |
| Support Level | $21.15 | $21.36 |
| Resistance Level | $22.04 | $21.67 |
| Average True Range (ATR) | 0.57 | 0.12 |
| MACD | 0.15 | -0.11 |
| Stochastic Oscillator | 75.46 | 67.09 |
OneSpaWorld Holdings Ltd is an operator of health and wellness centers onboard cruise ships and an operator of health and wellness centers at destination resorts all over the world. It offers a suite of premium health, fitness, beauty, and wellness services and products. The services provided by the company include body, salon, and skin care services and products, fitness classes and personal fitness training and pain management, detoxifying programs, and comprehensive body composition analyses among others. The company has only one single segment of Maritime and Destination Resorts.
Avadel Pharmaceuticals PLC is a specialty pharmaceutical company. The group focused on transforming medicines to transform lives. It provides solutions to the development of medications that address the challenges patients face with current treatment options. The company is engaged in the development of differentiated drug products for administration in various forms such as capsules, tablets, injectables etc. Its commercialized product LUMRYZ is an extended-release formulation of sodium oxybate indicated to be taken once at bedtime for the treatment of cataplexy or EDS in adults with narcolepsy. It operates in one segment, the development and commercialization of pharmaceutical products, including controlled-release therapeutic products based on its proprietary polymer-based technology.